KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Gains from Sales and Divestitures (2020 - 2022)

GoodRx Holdings' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $470000.0 for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures changed 0.0% year-over-year to $470000.0; the TTM value through Dec 2022 reached $470000.0, changed 0.0%, while the annual FY2022 figure was $470000.0, 0.0% changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $470000.0 at GoodRx Holdings, down from $743000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $16.4 million in Q4 2020 and bottomed at $118000.0 in Q2 2021.
  • The 3-year median for Gains from Sales and Divestitures is $472000.0 (2021), against an average of $2.2 million.
  • The largest annual shift saw Gains from Sales and Divestitures plummeted 97.14% in 2021 before it skyrocketed 334.75% in 2022.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $16.4 million in 2020, then tumbled by 97.14% to $470000.0 in 2021, then changed by 0.0% to $470000.0 in 2022.
  • Per Business Quant, the three most recent readings for GDRX's Gains from Sales and Divestitures are $470000.0 (Q4 2022), $743000.0 (Q3 2022), and $513000.0 (Q2 2022).